Watch RGBPP. Know when insiders buy.
One email the day a filing lands. Free.
RGBPP
Regen BioPharma Inc
0.00
−0.00 −31.03%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.4MP/E —DIV YIELD —FCF YIELD —REV TTM $237K +0.0%NET INCOME −$1.2MNET DEBT $107K52W 0.00 – 0.07SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Jun 30 | $59K | +0.0% | — | $25K | −$638K | — | 0.00 | −$24K | — | — | Aug 17 |
| Q2 2026 · Mar 31 | $59K | +0.0% | — | −$154K | $992K | — | 0.00 | −$63K | — | — | May 14 |
| Q1 2026 · Dec 31 | $59K | +0.0% | — | −$552K | −$968K | — | -0.01 | −$198K | — | — | Feb 13 |
| Q4 2025 · Sep 30derived | $59K | +0.0% | — | −$123K | −$572K | — | -0.02 | −$160K | — | — | Aug 17 |
| Q3 2025 · Jun 30 | $59K | +0.0% | — | −$41K | −$167K | — | -0.01 | −$56K | — | — | Aug 17 |
| Q2 2025 · Mar 31 | $59K | +86.7% | — | −$113K | −$19K | — | 0.00 | −$101K | — | — | May 14 |
| Q1 2025 · Dec 31 | $59K | +86.7% | — | −$61K | −$515K | — | -0.13 | −$66K | — | — | Feb 13 |
| Q4 2024 · Sep 30derived | $59K | — | — | −$85K | −$271K | — | -0.06 | −$207K | — | — | Dec 30 |
| Q3 2024 · Jun 30 | $59K | — | — | −$108K | −$130K | — | -0.03 | −$173K | — | — | Aug 11 |
| Q2 2024 · Mar 31 | $32K | — | — | −$101K | −$122K | — | -0.03 | −$209K | — | — | May 28 |
| Q1 2024 · Dec 31 | $32K | — | — | −$123K | −$145K | — | -0.04 | −$162K | — | — | May 16 |
| Q4 2023 · Sep 30 | −$51K | — | — | −$59K | −$325K | — | -0.10 | −$23K | — | — | May 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Sep 30 | $237K | — | −$339K | −$1.3M | -538.8% | -0.05 | −$384K | — | — | — | — |
| FY2024 · to Sep 30 | $237K | — | −$417K | −$668K | -282.5% | -0.16 | −$752K | — | — | — | — |
| FY2023 · to Sep 30 | $127K | — | −$687K | $1.2M | 913.8% | 0.29 | −$174K | — | — | — | — |
| FY2022 · to Sep 30 | $126K | — | −$340K | $2.4M | 1946.8% | 0.71 | −$607K | — | — | — | — |
| FY2021 · to Sep 30 | $61K | — | −$201K | −$6.8M | -11055.4% | -0.00 | −$1.1M | — | — | — | — |
| FY2020 · to Sep 30 | $110K | — | −$209K | $3.4M | 3104.0% | 0.00 | $19K | — | — | — | — |
Every number comes from Regen BioPharma Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.